Find the safety signal before it becomes a finding
Medical and scientific literature is a primary source for the benefit-risk evaluation of any medicinal product, and the obligation to screen it does not stop at the indexed databases. Local, non-indexed journals carry case reports too, in languages and formats that resist automation.
Cencora screens both. Global and local literature runs through a single validated workflow, with automated screening and translation handling the volume and in-country experts validating what the automation finds. Individual case safety reports (ICSRs) are created inside the same process and flow straight into signal management and aggregate reporting.
Cencora screens both. Global and local literature runs through a single validated workflow, with automated screening and translation handling the volume and in-country experts validating what the automation finds. Individual case safety reports (ICSRs) are created inside the same process and flow straight into signal management and aggregate reporting.
Close the gaps that manual screening leaves behind
Literature screening fails quietly. A missed local case report does not announce itself, and the gap only surfaces at inspection or when a signal is found late. Volume and language are usually what causes it.
Non-indexed local journals
Case reports appear in local journals that databases do not index, in print and in languages your screening process was never built to read.
Unmanageable screening volume
Hundreds of active substances generate thousands of references, and manual review at that scale invites the error it is meant to prevent.
Duplicate and fragmented intake
The same reference arrives from several sources, so reviewers spend their time reconciling intake instead of assessing what the literature says.
.jpg?h=768&iar=0&w=1365&hash=E0A6FCA47BA854226B601A260EE129BE)
Validated screening across every source your obligation covers
Cencora covers global and local literature across indexed databases and non-indexed local journals, plus European Medicines Agency (EMA) Medical Literature Monitoring (MLM).
VIGILIT uses automation and artificial intelligence (AI) to search, screen, quality-review, and de-duplicate, validated to Good Automated Manufacturing Practice (GAMP 5) and Code of Federal Regulations (CFR) Title 21 Part 11.
What we offer
Global and local screening
Screening across indexed databases, non-indexed local journals, and EMA Medical Literature Monitoring, for broad and integrated coverage.
Search strategy design
Search strings built per substance for high recall and precision, then maintained as your portfolio and the literature change.
Automated translation
Foreign-language references translated into English automatically, so a single centralized team can review literature from any market.
Expert review and quality control
In-country experts read the full article, not only the abstract, and validate the safety classification, backed by structured quality control.
Built-in case creation
Case reports generated inside the screening workflow in standard regulatory formats, with streamlined client notifications.
De-duplication and downstream integration
Automatic de-duplication of references, plus outputs that feed downstream ICSR processing, signal management, and aggregate reporting.
Why choose Cencora for literature surveillance
Qualified safety expertise
Qualified scientific and pharmacovigilance professionals review flagged references, supported by structured quality-control processes and in-country language skills. Icon: person with checkmark.
Validated technology platform
VIGILIT supports automated searches, AI-assisted screening and quality review, de-duplication, and client notifications on one validated platform. Icon: gear with document.
Scalable operating model
Web-based delivery scales with your volumes and connects to downstream ICSR processing, signal management, and aggregate reporting.
Expert insight
Two areas where AI is playing an important role at the local PV affiliate level are adverse event tracking and literature searches.
— José Miguel Rivas Romero
Harmonizing and safeguarding global and local pharmacovigilance processes
Related solutions
Safety monitoring and signal detection
Strengthen signal detection and safety monitoring with tailored review, validation, assessment, and action support across your pharmacovigilance activities.
Local affiliate pharmacovigilance management
Navigate complex local pharmacovigilance (PV) requirements with in-market expertise and centralized routine activities that improve efficiency, scalability, and compliance.
PharmaLex is now Cencora
Literature surveillance is part of our Commercialization support capability. Same team, same expertise, now with greater reach.
Need more information about literature surveillance?
Our team of experts is here to assist you. Whether you have questions or need more detailed information, don’t hesitate to get in touch. We’re dedicated to providing the support you need.